Premium
Identification of a WT1 protein‐derived peptide, WT1 187 , as a HLA‐A*0206‐restricted, WT1‐specific CTL epitope
Author(s) -
Li Zheyu,
Oka Yoshihiro,
Tsuboi Akihiro,
Fujiki Fumihiro,
Harada Yukie,
Nakajima Hiroko,
Masuda Tomoki,
Fukuda Yoko,
Kawakatsu Mai,
Morimoto Soyoko,
Katagiri Takamasa,
Tatsumi Naoya,
Hosen Naoki,
Shirakata Toshiaki,
Nishida Sumiyuki,
Kawakami Yutaka,
Udaka Keiko,
Kawase Ichiro,
Oji Yusuke,
Sugiyama Haruo
Publication year - 2008
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.2008.00069.x
Subject(s) - biology , epitope , ctl* , human leukocyte antigen , identification (biology) , peptide , virology , computational biology , genetics , immune system , antigen , ecology , cd8 , biochemistry
The Wilms' tumor gene WT1 is overexpressed in various kinds of hematopoietic malignancies as well as solid cancers, and this protein has been demonstrated to be an attractive target antigen for cancer immunotherapy. WT1‐specific CTL epitopes with a restriction of HLA‐A*2402 or HLA‐A*0201 have been already identified. In the present study it has been demonstrated that a 9‐mer WT1‐derived WT1 187 peptide, which had already been shown to elicit a WT1‐specific CTL response with a restriction of HLA‐A*0201, can also elicit a CTL response with a restriction of HLA‐A*0206. In all three different HLA‐A*0206 + healthy donors examined, WT1 187 peptide‐specific CTL could be generated from peripheral blood mononuclear cells, and the CTL showed cytotoxic activity that depended on dual expression of WT1 and HLA‐A*0206 molecules. The present study describes the first identification of a HLA‐A*0206‐restricted, WT1‐specific CTL epitope. The present results should help to broaden the application of WT1 peptide‐based immunotherapy from only HLA‐A*0201‐positive to HLA‐A*0206‐positive cancer patients as well.